12:49:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-03-30 Ordinarie utdelning ZEAL 0.00 DKK
2023-03-29 Årsstämma 2023
2023-03-02 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-09 Ordinarie utdelning ZEAL 0.00 DKK
2022-04-06 Årsstämma 2022
2022-03-10 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-16 Ordinarie utdelning ZEAL 0.00 DKK
2021-04-15 Årsstämma 2021
2021-03-11 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 Ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2020
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 Ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2019
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2018
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 Ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2016
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 Ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2015
2015-03-12 Bokslutskommuniké 2014
2014-11-07 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-06 Kapitalmarknadsdag 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-04-29 Årsstämma 2014
2014-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2014-03-20 Bokslutskommuniké 2013
2013-11-15 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-05-15 Kvartalsrapport 2013-Q1
2013-04-30 Årsstämma 2013
2013-04-30 Ordinarie utdelning ZEAL 0.00 DKK
2013-03-14 Bokslutskommuniké 2012
2012-11-29 Kapitalmarknadsdag 2012
2012-04-26 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-25 Kapitalmarknadsdag 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-12 Kvartalsrapport 2011-Q1
2011-04-29 Ordinarie utdelning ZEAL 0.00 DKK
2011-04-28 Årsstämma 2011

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är verksamma inom bioteknik. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg.
2021-06-28 22:05:00

Company announcement – No. 42/ 2021

ZEALAND PHARMA A/S - SHARE BUY-BACK PROGRAM UNDER SAFE HARBOUR TO AQUIRE DANISH COMMON STOCK FOR EMPLOYEE INCENTIVE PROGRAMS

On 29 June 2021, Zealand Pharma A/S ("Zealand") will initiate a share repurchase program in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbor Regulation”). 

Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program. Danske Bank A/S will buy back shares on behalf of Zealand and make related trading decisions independently of and without influence by Zealand.

The share repurchase program will be implemented under the following terms:

  • The maximum total consideration for shares bought back will be DKK 32,070,896;
  • The maximum number of shares to be bought back will be 154,187;
  • In accordance with the Safe Harbour Regulation, the shares shall be repurchased by Danske Bank on the trading venue (Nasdaq Copenhagen) where the shares are admitted to trading;
  • The maximum number of shares that may be purchased per daily market session may not exceed 25% of the average daily volume of Zealand's shares traded on Nasdaq Copenhagen during the preceding 20 trading days; and
  • Shares cannot be bought back at a price exceeding the higher of (i) the share price of the last independent transaction on Nasdaq Copenhagen A/S, and (ii) the highest independent bid on the shares on Nasdaq Copenhagen A/S, however, regardless of the foregoing, shares cannot be bought back at a price exceeding DKK 208 per share.

On a weekly basis, Zealand will announce transactions made under the share repurchase program in accordance with the reporting obligations imposed by the Safe Harbour Regulation.

Zealand may terminate the program at any time, which will be announced through Nasdaq Copenhagen A/S, if relevant.

The share buy-back program will start on June 29 , 2021 and will be completed no later than July 29, 2021.

Prior to launch of the share repurchase program, Zealand holds 64,223 treasury shares, corresponding to 0.01% of the total share capital.

The share repurchase program is launched with reference to the authorization to acquire treasury shares granted by the general meeting on April 15, 2021. The authorization is valid until Zealand's next annual general meeting and allows Zealand to acquire shares with a total nominal value of up to 10% of its share capital at any given time.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development.. In the United States Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes and Zegalogue® for the treatment of severe hypoglycemia in pediatric patients with diabetes aged 6 years and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

V-go® and Zegalouge® are registered trademarks of Zealand Pharma A/S

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.


Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
E-Mail: investors@zealandpharma.com


Zealand Pharma Media Relations
David Rosen 
Argot Partners 
E-Mail: media@zealandpharma.com